Recombinant Human EphA7 Fc Chimera Protein, CF

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

EphA7, also known as Mdk1, Hek11, Ehk3, Ebk, and Cek11, is a 115 ‑ 120 kDa glycosylated member of the Eph family of transmembrane receptor tyrosine kinases (1, 2). The A and B classes of Eph proteins are distinguished by Ephrin ligand binding preference but have a common structural organization. EphA7 preferentially binds to and is activated by Ephrin‑A1, ‑A2, ‑A3, ‑A4, and ‑A5 (3 ‑ 6). Eph‑Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression. The 532 amino acid (aa) extracellular domain (ECD) of human EphA7 contains an N‑terminal Ephrin binding region, a cysteine‑rich region, and two fibronectin type III domains (FnIII). The 421 aa cytoplasmic domain contains the tyrosine kinase domain and a sterile alpha motif (SAM) (7). Within the ECD, human EphA7 shares 98% aa sequence identity with mouse and rat EphA7. Alternate splicing generates secreted isoforms of human EphA7 that are truncated either before or following the first FnIII domain (7, 8). In mouse, EphA7 is expressed in discrete regions of the developing and adult neocortex (4, 9 ‑ 12), Purkinje layer of the cerebellum (10), limbic system (4, 9, 11, 12), visual and auditory systems (10, 11, 13), and the peripheral sensory nervous system (10, 11). EphA7 functions as a repulsive guidance molecule during the targeting of retinal axons to the superior colliculus  and of neocortical axons to the thalamus (4, 9, 13). EphA7 is also expressed in mesenchymal cells along routes of axon innervation during limb development (14). EphA7 ligands are expressed in a complementary pattern during embryogenesis (3, 9, 13, 14). EphA7 is selectively expressed in early stages of the B cell lineage, and a 50 kDa secreted form is produced by mature peripheral B and T cells (6, 15). This isoform is also expressed in human lung carcinoma (8). EphA7 can be up or down‑regulated in a variety of human cancers (6, 16, 17).

We have publications tested in 2 confirmed species: Human, N/A.

We have publications tested in 2 applications: Bioassay, ELISA Capture.

Showing Publications 1 - 2 of 2.

Publications using 6756-A7	Applications	Species
El Fakiri, M;Regupathy, AR;Uhlmann, L;Ayada, N;Geis, NM;Domogalla, LC;Lahdenranta, J;Blakeman, B;Wood, F;Meyer, PT;Huxley, P;Eder, M;Mudd, GE;Eder, AC; Development and preclinical characterization of a novel radiotheranostic EphA2-targeting bicyclic peptide Theranostics 2024-08-06 [PMID: 39239524] (Bioassay, Human)	Bioassay	Human
JH Cha, LC Chan, YN Wang, YY Chu, CH Wang, HH Lee, W Xia, WC Shyu, SP Liu, J Yao, CW Chang, FR Cheng, J Liu, SO Lim, JL Hsu, WH Yang, GN Hortobagyi, C Lin, L Yang, D Yu, LB Jeng, MC Hung Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer The Journal of Biological Chemistry, 2022-03-10;0(0):101817. 2022-03-10 [PMID: 35278434] (ELISA Capture, N/A)	ELISA Capture	N/A

Array 6756-A7

• EphA7 Antibodies
• EphA7 Proteins and Enzymes